Toshiro Sato

Kyushu University — Japan

Medicine · Health Sciences

75h-index42.7kcitations530works3.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Cells and Metastasis(79), Lung Cancer Research Studies(54), Neuroendocrine Tumor Research Advances(49), Metastasis and carcinoma case studies(45), Digestive system and related health(41)

Publications517 total

Niche-preserving transplantation promotes functional engraftment of intestinal organoids in rat short bowel syndrome
Cell stem cell·2025Open Access
Comparison by Gender and Age and Their Mutual Relations with Center of Pressure Variables
American journal of sports science and medicine·2025Open Access
Modeling the metastatic tumor microenvironment: a co-culture platform of lung cancer and blood vessel organoids for drug evaluation
Scientific Reports·2025Open Access
Organoid-based precision cancer modeling: New frontier in lung cancer research
Cell Reports·2025Open Access
Reply
Gastroenterology·2025Open Access
In-Situ Current Measurement for Accurate Turn-on/Turn-off Loss Evaluation using an Optical Probe Current Sensor
2025
Deep visual proteomics reveals an in vivo-like phenotype of orthotopically transplanted human colon organoids
Cell Systems·2025· 1 citedOpen Access
Supplementary Figure S2. from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Figshare·2025Open Access
Supplementary Table S2. from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Figshare·2025Open Access
Supplementary Table S3 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
2025Open Access
Supplementary Table S1 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Figshare·2025Open Access
Supplementary Figure S5. from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
2025Open Access
Supplementary Figure S4 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Figshare·2025Open Access
Supplementary Figure S1. from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
2025Open Access
Supplementary Figure S3 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
2025Open Access
Data from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
2025Open Access
Figure 2 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
2025Open Access
Figure 5 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
2025Open Access
Supplementary Figure S2. from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
2025Open Access
Supplementary Figure S4 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
2025Open Access
page 1 of 26Next →

Frequent Co-authors

Hans Clevers(19), Masayuki Fujii(14), Takanori Kanai∥(14), Mami Matano(13), Yuki Ohta(10), Johan H. van Es(9), Mariko Shimokawa(9), Kosaku Nanki(9), Meritxell Huch(8), Ai Takano(8), Shinya Sugimoto(8), Toshifumi Hibi∥(8), Marc van de Wetering(7), Kohta Toshimitsu(7), Daniel E. Stange(6), Shoichi Date(6), Kenta Kawasaki(6), Shingo Nishikori(6), Sirirat Takahashi(6), Nobuhiko Kamada(6)